Cougar Biotechnology Presents CB7630 Phase I Data at Prostate Cancer Foundation Scientific Retreat
PSA Rising addition: The data for this trial were originally presented in the UK:
British Journal of Cancer (2004) 90, 2317 - 2325.
doi:10.1038/sj.bjc.6601879 Published online 18 May 2004
Hormonal impact of the 17 -hydroxylase / C 17,20 -lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
Los Angeles, CA, October 25, 2004 - Cougar Biotechnology, Inc, a privately held
biotechnology company, announced that results from the Phase I clinical trials of CougarÂs
investigational drug, CB7630 (abiraterone acetate) were presented at the Prostate Cancer
Foundation Scientific Retreat on October 23rd. The Phase I trials of CB7630 were conducted at
the Cancer Research UK Centre for Cancer Therapeutics/Institute of Cancer Research and the
Royal Marsden Hospital in the United Kingdom, and the results were published in the British
Journal of Cancer in June, 2004.
The presentation, entitled "CB7630 (Abiraterone Acetate): A Novel Targeted Oral Therapy for
Hormone-Refractory Prostate Cancer" provided an overview of the clinical data from three dose
escalating clinical studies of CB7630 given as a single agent to prostate cancer patients. In the
two single dose clinical studies, CB7630 was given to castrate and noncastrate prostate cancer
patients at doses ranging from 10 to 500 mg. 4 out of 6 castrate patients treated with a single
dose of 500 mg of CB7630 achieved suppression of testosterone to levels less than 0.14 nmol/l.
In the multiple dose study, CB7630 was given at a dose of either 500 mg or 800 mg for 12 days
to 6 previously treated prostate cancer patients. All patents treated at the 500 mg and 800 mg
level experienced suppression of testosterone to castrate levels (less than 2.0 nmol/l). In
addition, of the patients treated with 800 mg daily, 2 out of 3 patients had complete suppression
of testosterone down to levels that are comparable to those typically seen in patients that are
being treated with LHRH agonists (less than 0.7 nmol/l). Treatment with CB7630 was well
tolerated with no biochemical or hematological side effects.
"Because the initial clinical trials of CB7630 were performed in Europe, researchers in the US
have limited experience with the drug. I am therefore pleased to be able to present the clinical
data with this novel prostate cancer drug at a prominent meeting like the Prostate Cancer
Foundation Scientific Retreat," said Dr. Arie Belldegrun, MD, FACS, Chairman of the
Scientific Advisory Board of Cougar Biotechnology. "We are pleased to have been selected to
present our data at this meeting and view it as an important opportunity to build awareness of the
drug prior to the advancement of the clinical development of CB7630 that is currently scheduled
for next year," added Alan H. Auerbach, Chief Executive Officer and President of Cougar
Biotechnology. "We hope to continue our relationship with the Prostate Cancer Foundation
throughout the course of the clinical development of CB7630."
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based private biotechnology company established to in-license and develop early clinical stage drugs, with a specific focus on the field of oncology. Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
